Pharmaceutical companies have struggled to package GLP-1 agonists and other peptide-based drugs into pill form because peptides, chains of amino acids that are the building blocks of protein ...

Pharmaceutical companies have struggled to package GLP-1 agonists and other peptide-based drugs into pill form because peptides, chains of amino acids that are the building blocks of protein, are ...

A study published in Current Neuropharmacology reveals a potential link between Glucagon-like Peptide-1 (GLP-1) receptor agonists, commonly used in drugs like Ozempic, and an increased risk of ...

Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common chronic liver disease globally and is currently estimated to affect up to 38% of the global adult population. NAFLD is a ...